A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsStéphanie Gaillard, Nilofer S. Azad, Melinda Downs et al.|Cancer|2019Cited by 56
Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control studyVesal Yaghoobi, David L. Rimm, Myrto Moutafi et al.|Breast Cancer Research|2021Cited by 8
Quantitative Assessment of the Immune Microenvironment in African American Triple Negative Breast Cancer: A Case Control StudyVesal Yaghoobi, David L. Rimm, Lajos Pusztai et al.|Research Square|2021Cited by 0